Tags

Type your tag names separated by a space and hit enter

Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case.
Prev Med. 2022 01; 154:106890.PM

Abstract

We present epidemiological data to examine trends in COVID-19 incidence, morbidity and mortality in Israel as well as changes in vaccine effectiveness, and discuss the impact of the delta variant and the third, "booster", vaccine. A retrospective-archive study was conducted from February 27th 2020 to October 16th, 2021. Data were obtained from the Israeli Ministry of Health's open COVID 19 database, including PCR-confirmed cases, number hospitalized - including severe cases, death rate, all by age and vaccination status, case fatality rate and changing effectiveness of the vaccine. After three COVID waves, confirmed cases rose from under 30 new daily cases in mid-June to a high of 11,000 in early September 2021. Severe hospitalized cases and death rates were lower than in previous waves and largely restricted to those not fully vaccinated. In the first three months of the vaccination campaign, non-vaccinated population demonstrated much higher morbidity rates. Four months after vaccination began, this gap was attenuated, with low rates of infection and hospitalization in all groups. The gap was regained following uptake of the third vaccine. Data from the fourth wave show reduced hospitalizations and mortality compared to previous waves and suggest that this may be related to high vaccine coverage. These trends suggest that countries with high vaccination might adopt a more permissive approach towards COVID even in the face of new variants.

Authors+Show Affiliations

The Gertner Institute for Epidemiology and Health Policy Research, Ramat Gan, Israel. Electronic address: mors@gertner.health.gov.il.The Gertner Institute for Epidemiology and Health Policy Research, Ramat Gan, Israel. Electronic address: vickimg@gertner.health.gov.il.The Gertner Institute for Epidemiology and Health Policy Research, Ramat Gan, Israel; School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: rachelwm@gertner.health.gov.il.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34800471

Citation

Saban, Mor, et al. "Changes in Infectivity, Severity and Vaccine Effectiveness Against Delta COVID-19 Variant Ten Months Into the Vaccination Program: the Israeli Case." Preventive Medicine, vol. 154, 2022, p. 106890.
Saban M, Myers V, Wilf-Miron R. Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case. Prev Med. 2022;154:106890.
Saban, M., Myers, V., & Wilf-Miron, R. (2022). Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case. Preventive Medicine, 154, 106890. https://doi.org/10.1016/j.ypmed.2021.106890
Saban M, Myers V, Wilf-Miron R. Changes in Infectivity, Severity and Vaccine Effectiveness Against Delta COVID-19 Variant Ten Months Into the Vaccination Program: the Israeli Case. Prev Med. 2022;154:106890. PubMed PMID: 34800471.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case. AU - Saban,Mor, AU - Myers,Vicki, AU - Wilf-Miron,Rachel, Y1 - 2021/11/17/ PY - 2021/08/09/received PY - 2021/11/08/revised PY - 2021/11/14/accepted PY - 2021/11/21/pubmed PY - 2022/1/11/medline PY - 2021/11/20/entrez KW - COVID-19 KW - Delta KW - Infectious diseases KW - Israel KW - Vaccination KW - Vaccine effectiveness KW - Variant SP - 106890 EP - 106890 JF - Preventive medicine JO - Prev Med VL - 154 N2 - We present epidemiological data to examine trends in COVID-19 incidence, morbidity and mortality in Israel as well as changes in vaccine effectiveness, and discuss the impact of the delta variant and the third, "booster", vaccine. A retrospective-archive study was conducted from February 27th 2020 to October 16th, 2021. Data were obtained from the Israeli Ministry of Health's open COVID 19 database, including PCR-confirmed cases, number hospitalized - including severe cases, death rate, all by age and vaccination status, case fatality rate and changing effectiveness of the vaccine. After three COVID waves, confirmed cases rose from under 30 new daily cases in mid-June to a high of 11,000 in early September 2021. Severe hospitalized cases and death rates were lower than in previous waves and largely restricted to those not fully vaccinated. In the first three months of the vaccination campaign, non-vaccinated population demonstrated much higher morbidity rates. Four months after vaccination began, this gap was attenuated, with low rates of infection and hospitalization in all groups. The gap was regained following uptake of the third vaccine. Data from the fourth wave show reduced hospitalizations and mortality compared to previous waves and suggest that this may be related to high vaccine coverage. These trends suggest that countries with high vaccination might adopt a more permissive approach towards COVID even in the face of new variants. SN - 1096-0260 UR - https://www.unboundmedicine.com/medline/citation/34800471/Changes_in_infectivity_severity_and_vaccine_effectiveness_against_delta_COVID_19_variant_ten_months_into_the_vaccination_program:_The_Israeli_case_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-7435(21)00463-1 DB - PRIME DP - Unbound Medicine ER -